Chang, Gee-Chen
Lam, David Chi-Leung
Tsai, Chun-Ming
Chen, Yuh-Min
Shih, Jin-Yuan
Aggarwal, Shyam
Wang, Shuhang
Kim, Sang-We
Kim, Young-Chul
Wahid, Ibrahim
Li, Rubi
Lim, Darren Wan-Teck
Sriuranpong, Virote
Chan, Raymond Tsz-Tong
Lorence, Robert M.
Carriere, Philippe
Raabe, Christina
Cseh, Agnieszka
Park, Keunchil
Funding for this research was provided by:
Boehringer Ingelheim Inc.
Article History
Received: 5 June 2020
Accepted: 1 January 2021
First Online: 30 March 2021
Compliance with ethical standards
:
: DC-LL received research funding from Astrazeneca, Boehringer Ingelheim, and Novartis for research projects on respiratory diseases in 2019. J-YS received honoraria from AstraZeneca, Roche, Boehringer Ingelheim, Eli Lilly, Pfizer, Novartis, MSD, Ono Pharmaceutical, Chugai Pharmaceutical; and received funding for other items (e.g. trips, travel or gifts) from Roche, MSD, Chugai Pharmaceutical, Bristol-Myers Squibb and Pfizer. SA reports advisory board meeting relationship with Boehringer Ingelheim, Dr Reddy’s Laboratories and Intas Biopharmaceuticals. Y-CK received honoraria and research funding from Boehringer Ingelheim, AstraZeneca, and Roche. RL received honoraria from Boehringer Ingelheim. DW-TL received honoraria from Bristol-Myer Squibb, Merck, Taiho, Pfizer, and Roche; and received research funding from Bristol-Myer Squibb. VS reports advisory board meeting relationship with MSD, Novartis, Pfizer, Roche, Eisai, and Amgen; received speaker fees from AstraZeneca, Novartis, Roche, Pfizer, Sanofi, Eisai, Boehringer Ingelheim, Taiho, MSD, BMS, and Amgen; and received clinical research funding through institution from AstraZeneca, Novartis, Roche, Pfizer and MSD. RML reports former employment with and current consultancy for Boehringer Ingelheim Pharmaceuticals, Inc. PC reports employment with Boehringer Ingelheim Pharmaceuticals, Inc. CR reports employment with Boehringer Ingelheim International GmbH. AC reports employment with Boehringer Ingelheim RCV GmbH & Co KG. KP reports employment with/leadership position for/advisory role for: AbbVie, AMGEN, Astellas Pharma, AstraZeneca, BluePrint, BMS, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, GSK, Hanmi, Incyte, Kyowa Hakko Kirin, LOXO, Merck KGaA, MSD, Novartis, ONO Pharmaceutical and Roche; and received research funding from AstraZeneca and MSD. G-CC, C-MT, Y-MC, SW, IW, S-WK, and RT-TC report no conflicts of interest.